Epilepsy
📧 Sign up to get email alerts when something new happens for Epilepsy.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2013-02-08FDA Approved: VIMPAT — Supplemental Application (UCB, Inc.)
The FDA approved a supplemental application for VIMPAT (lacosamide) submitted by UCB, Inc., expanding/updating its labeling for epilepsy.
-
FDA approval · 2013-02-08FDA Approved: VIMPAT — Supplemental Application (UCB, Inc.)
FDA approved a supplemental application for VIMPAT (lacosamide) from UCB, Inc., resulting in a labeling update/expanded use for the anticonv…
-
CLINICAL_TRIALS trial_result · 2013-02-07Clinical Trial Update: An add-on Study of E2007 in Patients With Refractory Partial Seizures Uncontrolled With Other Anti-epileptic Drugs (AEDs) [Phase 2]
Phase 2 add-on study of E2007 in patients with refractory partial seizures uncontrolled with other anti-epileptic drugs has completed enroll…
-
CLINICAL_TRIALS trial_result · 2013-02-06Clinical Trial Update: A Study to Evaluate the Safety and Tolerability and Explore the Efficacy of Zonisamide as add-on Therapy in Elderly Patients With Refractory Partial Seizures [Phase 4]
Phase 4 trial evaluating zonisamide as add-on therapy for elderly patients with refractory partial seizures; the study was terminated with r…
-
FDA approval · 2013-02-05FDA Approved: VIMPAT — Supplemental Application (UCB, Inc.)
FDA approved a supplemental application for VIMPAT (lacosamide) submitted by UCB, Inc., marking an approved modification to the product labe…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2013-02-05Clinical Trial Update: Rufinamide Given as Adjunctive Therapy in Participants With Refractory Partial Seizures [Phase 3]
Phase 3 clinical trial update on Rufinamide as adjunctive therapy for refractory partial seizures in epilepsy patients.
-
CLINICAL_TRIALS trial_result · 2013-01-29Clinical Trial Update: Carisbamate Retention Study (CaReS): Comparative Study on the Long Term Effectiveness, Safety and Tolerability of Carisbamate Compared to Two Other Frequently Prescribed Anti-epileptic Drugs (AEDs) in Patients With Epilepsy. [Phase 3]
Phase 3 clinical trial comparing the long-term effectiveness, safety, and tolerability of carisbamate to two other frequently prescribed ant…
-
FDA approval · 2013-01-28FDA Approved: DIAZEPAM — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approved a supplemental application for diazepam from Teva Pharmaceuticals USA, Inc. The action represents an additional approval or mod…
-
FDA approval · 2013-01-28FDA Approved: CLONAZEPAM — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approved a supplemental application for clonazepam from Teva Pharmaceuticals USA, Inc.
-
CLINICAL_TRIALS trial_result · 2013-01-24Clinical Trial Update: A Study of the Effectiveness, Safety, and Tolerability of Carisbamate as Add-On Therapy in Patients With Partial Onset Seizures. [Phase 3]
Phase 3 trial updating on the effectiveness, safety, and tolerability of carisbamate as add-on therapy for partial-onset seizures. The study…
-
CLINICAL_TRIALS trial_result · 2013-01-24Clinical Trial Update: An Open-Label Extension Study to Evaluate the Safety and Effectiveness of RWJ 333369 in Patients With Epilepsy [Phase 2]
An open-label extension study evaluating the safety and effectiveness of RWJ 333369 in epilepsy has completed Phase 2.
-
CLINICAL_TRIALS trial_result · 2013-01-24Clinical Trial Update: An Open-Label Extension Study of the Effectiveness and Safety of the Investigational Compound RWJ-333369 in Patients With Epilepsy [Phase 2]
Open-label extension study results for RWJ-333369 in epilepsy have completed Phase 2 evaluation, focusing on safety and effectiveness in pat…
-
CLINICAL_TRIALS trial_result · 2013-01-23Clinical Trial Update: Effectiveness and Safety Study for RWJ-333369 as Adjunctive Therapy in Korean and Japanese Patients With Partial Onset Seizures [Phase 3]
A Phase 3 trial evaluating RWJ-333369 as adjunctive therapy for partial onset seizures in Korean and Japanese patients was terminated.
-
CLINICAL_TRIALS trial_result · 2013-01-21Clinical Trial Update: SANTE - Stimulation of the Anterior Nucleus of the Thalamus for Epilepsy [Phase 3]
Phase 3 clinical trial update on Medtronic's SANTE deep brain stimulation system for epilepsy; the trial has completed and results have been…
-
CLINICAL_TRIALS research · 2013-01-21Clinical Trial Update: Neuroimaging Predictors of Treatment Failure in Adult New-onset Epilepsy
This clinical trial update discusses research on neuroimaging predictors of treatment failure in adults with new-onset epilepsy. The sponsor…
-
FDA approval · 2013-01-18FDA Approved: LAMOTRIGINE EXTENDED RELEASE — Original Application (Par Health USA, LLC)
The FDA approved Par Health USA, LLC's Lamotrigine Extended Release as a new generic product under an original ANDA.
-
CLINICAL_TRIALS trial_result · 2013-01-16Clinical Trial Update: Long Term Effectiveness and Safety Study for RWJ-333369 as Adjunctive Therapy in Korean and Japanese Patients With Partial Onset Seizures [Phase 3]
This clinical trial update notes the completion of a Phase 3 long-term effectiveness and safety study of RWJ-333369 as adjunctive therapy fo…
-
CLINICAL_TRIALS trial_result · 2013-01-15Clinical Trial Update: Assessing The Long-Term Safety And To Explore The Long-Term Efficacy Of Zonisamide As Monotherapy In Newly Diagnosed Partial Seizures [Phase 3]
Phase 3 trial assessing long-term safety and efficacy of zonisamide as monotherapy for newly diagnosed partial seizures; results posted.
-
CLINICAL_TRIALS trial_result · 2013-01-09Clinical Trial Update: Study on Serum Zinc and Selenium Levels in Epileptic Patients
A completed clinical trial evaluating serum zinc and selenium levels in patients with epilepsy, sponsored by Arak University of Medical Scie…
-
CLINICAL_TRIALS guidance · 2013-01-07Clinical Trial Update: Policy on Optimal Epilepsy Management [NA]
This clinical trial update outlines policy guidance for optimal epilepsy management, highlighting recommended practices for clinicians.
-
FDA approval · 2012-12-26FDA Approved: PHENYTOIN — Original Application (Rising Pharma Holdings, Inc.)
FDA approves Rising Pharma's original ANDA for phenytoin, permitting a generic version of this antiseizure drug for seizure disorders.
-
FDA approval · 2012-12-26FDA Approved: LAMOTRIGINE EXTENDED-RELEASE — Original Application (Par Health USA, LLC)
The FDA approved Par Health USA, LLC's Lamotrigine Extended-Release as an original-application generic, to be marketed for the approved epil…
-
CLINICAL_TRIALS trial_result · 2012-12-24Clinical Trial Update: A Drug Interaction Study of Valproic Acid and Single-dose Paliperidone Extended-Release (ER) in Healthy Men [Phase 1]
Phase 1 study assessing the drug interaction between valproic acid and a single dose of paliperidone extended-release in healthy men; the st…
-
FDA approval · 2012-12-11FDA Approved: SABRIL — Supplemental Application (Lundbeck Pharmaceuticals LLC)
The FDA approved Lundbeck's supplemental application for SABRIL (vigabatrin), updating the labeling per NDA020427. This approval reflects ch…
-
FDA approval · 2012-12-11FDA Approved: SABRIL — Supplemental Application (Lundbeck Pharmaceuticals LLC)
FDA approved a supplemental application for SABRIL (vigabatrin) from Lundbeck Pharmaceuticals LLC. The action typically updates labeling or …